Tech Company Financing Transactions
Profectus BioSciences Funding Round
Profectus BioSciences, based in Baltimore, raised $5 million in funding from Cross Atlantic Capital Partners and private investors.
Transaction Overview
Company Name
Announced On
7/22/2009
Transaction Type
Venture Equity
Amount
$5,000,000
Round
Series C
Investors
Cross Atlantic Capital Partners (Lead Investor) (Donald Caldwell)
Proceeds Purpose
This funding provides us with additional working capital to support general corporate activities, as well as additional R&D activities.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
6411 Beckley St.
Baltimore, MD 21224
USA
Baltimore, MD 21224
USA
Phone
Website
Email Address
Overview
Profectus BioSciences, Inc. identifies and commercializes technologies intended to reduce the morbidity and mortality caused by viral diseases, especially Human Immunodeficiency Virus (HIV).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Thomas Paese
Chief Operating Officer
Jeffrey Meshulam
Chief Scientific Officer
John Eldridge
VP - Operations
Terry Higgins
Browse more venture capital transactions:
Prev: 7/22/2009: eMeter venture capital transaction
Next: 7/23/2009: Augmenix venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs